Since AURKA and AURKB gene expression has been associated with the activation of tyrosine kinase signaling in MPN, presented potential contribution to the malignant phenotype, and are putative druggable21–23, we selected these two genes for further validation. This evidence concerns the gene AURKB and myeloproliferative disorder.